Literature DB >> 12914593

Different corticostriatal patterns of L-DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine.

Ola Gefvert1, Leif H Lindström, Nicholas Waters, Susanna Waters, Arvid Carlsson, Joakim Tedroff.   

Abstract

Positron emission tomography (PET) has been shown to be of great importance in elucidating the mechanism of action of antipsychotic drugs. In psychotic patients L-[11C]DOPA PET has been used to demonstrate some differences in dopaminergic activity compared with that in healthy volunteers. Ten healthy volunteers were investigated with PET and L-[11C]DOPA. Ten drug-free patients with psychosis, nine stable schizophrenics treated with clozapine, and nine stable patients treated with classical antipsychotics were also investigated with L-[11C]DOPA. Principal-component analysis was employed for the analysis of L-[11C]DOPA Ki values across a number of corticostriatal brain regions. These data revealed a significant three-component model with clear-cut separation between healthy controls and patients with unmedicated schizophrenia. Stable optimal treatment with either classical neuroleptics or clozapine partially, albeit differentially, reversed the aberrant patterns seen in drug-free schizophrenia. It can thus be concluded that schizophrenia is associated with abnormal patterns of L-[11C]DOPA utilization in corticostriatal systems. Treatment with clozapine or classical neuroleptics induces partial, albeit differential, normalization of the abnormal patterns seen in untreated schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12914593     DOI: 10.1111/1467-9450.00347

Source DB:  PubMed          Journal:  Scand J Psychol        ISSN: 0036-5564


  6 in total

Review 1.  Dopaminergic dysfunction in schizophrenia: salience attribution revisited.

Authors:  Andreas Heinz; Florian Schlagenhauf
Journal:  Schizophr Bull       Date:  2010-05-07       Impact factor: 9.306

Review 2.  Epigenetics and biomarkers in the staging of neuropsychiatric disorders.

Authors:  Trevor Archer; Richard J Beninger; Tomas Palomo; Richard M Kostrzewa
Journal:  Neurotox Res       Date:  2010-03-17       Impact factor: 3.911

3.  Clinical correlation but no elevation of striatal dopamine synthesis capacity in two independent cohorts of medication-free individuals with schizophrenia.

Authors:  Daniel Paul Eisenberg; Philip D Kohn; Catherine E Hegarty; Nicole R Smith; Shannon E Grogans; Jasmin B Czarapata; Michael D Gregory; José A Apud; Karen F Berman
Journal:  Mol Psychiatry       Date:  2021-11-17       Impact factor: 15.992

Review 4.  [Structural and functional brain changes in schizophrenic disorders. Indications of early neuronal developmental disturbances?].

Authors:  P Kalus; P Falkai; A Heinz
Journal:  Nervenarzt       Date:  2008-03       Impact factor: 1.214

5.  Altered pattern of brain dopamine synthesis in male adolescents with attention deficit hyperactivity disorder.

Authors:  Hans Forssberg; Elisabeth Fernell; Susanna Waters; Nicholas Waters; Joakim Tedroff
Journal:  Behav Brain Funct       Date:  2006-12-04       Impact factor: 3.759

6.  Relation between dopamine synthesis capacity and cell-level structure in human striatum: a multi-modal study with positron emission tomography and diffusion tensor imaging.

Authors:  Hiroshi Kawaguchi; Takayuki Obata; Harumasa Takano; Tsuyoshi Nogami; Tetsuya Suhara; Hiroshi Ito
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.